Lipotalon (Dexamethasone Palmitate)

After injection, dexamethasone palmitate is converted to dexamethasone, which binds glucocorticoid receptors inside cells. The activated receptor complex alters gene transcription, suppressing pro‑inflammatory cytokines, reducing leukocyte migration, and stabilising cell membranes, resulting in potent local anti‑inflammatory and immunomodulatory effects.

The specific dose of Lipotalon is determined by the prescribing clinician based on the indication, injection site, patient weight, and clinical response. Healthcare professionals set the appropriate volume and concentration for each individual case.

Safety data for dexamethasone palmitate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To request Lipotalon, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Lipotalon delivers dexamethasone palmitate, a pro‑drug that provides a controlled release of dexamethasone at the injection site. Compared with shorter‑acting agents like triamcinolone, it may offer prolonged anti‑inflammatory activity with potentially fewer systemic peaks, though clinical choice depends on physician preference and patient factors.

Lipotalon should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations. Do not freeze; inspect the vial for particulate matter before use.

Lipotalon is administered by a qualified healthcare professional via sterile infiltration, intra‑articular or peri‑articular injection. The injection site is prepared aseptically, and the appropriate volume is delivered using a suitable needle gauge under standard clinical guidelines.

Serious risks include adrenal suppression, systemic infection, osteonecrosis of bone, severe hyperglycaemia, and rare allergic reactions such as anaphylaxis. Patients should be monitored for signs of these events, especially after repeated injections or high cumulative doses.

Lipotalon is contraindicated in patients with active systemic fungal infections, known hypersensitivity to dexamethasone or any formulation component, and in those where local infection is present at the intended injection site. Caution is also advised for patients with uncontrolled diabetes or severe osteoporosis.